Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 112

1.

A randomized, double-blind, placebo-controlled, crossover study to evaluate the human abuse liability of solriamfetol, a selective dopamine and norepinephrine reuptake inhibitor.

Carter LP, Henningfield JE, Wang YG, Lu Y, Kelsh D, Vince B, Sellers E.

J Psychopharmacol. 2018 Oct 1:269881118796814. doi: 10.1177/0269881118796814. [Epub ahead of print]

PMID:
30269642
2.

Discovery and engineering of enhanced SUMO protease enzymes.

Lau YK, Baytshtok V, Howard TA, Fiala BM, Johnson JM, Carter LP, Baker D, Lima CD, Bahl CD.

J Biol Chem. 2018 Aug 24;293(34):13224-13233. doi: 10.1074/jbc.RA118.004146. Epub 2018 Jul 5.

PMID:
29976752
3.

Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor.

Baladi MG, Forster MJ, Gatch MB, Mailman RB, Hyman DL, Carter LP, Janowsky A.

J Pharmacol Exp Ther. 2018 Aug;366(2):367-376. doi: 10.1124/jpet.118.248120. Epub 2018 Jun 11.

PMID:
29891587
4.

Evaluation of the effect of JZP-110 in patients with narcolepsy assessed using the Maintenance of Wakefulness Test censored to 20 minutes.

Ruoff C, Bogan RK, Emsellem H, Feldman N, Lankford A, Bream G, Khayrallah M, Lu Y, Carter LP, Black J.

Sleep Med. 2017 Jul;35:12-16. doi: 10.1016/j.sleep.2017.03.025. Epub 2017 Apr 22.

5.

A Case of Exertional Rhabdomyolysis: A Cheer for Standardizing Inpatient Management and Prevention.

Yang Y, Carter LP, Cook RE, Paul E, Schwartz KR.

Hosp Pediatr. 2016 Dec;6(12):753-756. Epub 2016 Nov 9. No abstract available.

6.

Impact of sodium oxybate, modafinil, and combination treatment on excessive daytime sleepiness in patients who have narcolepsy with or without cataplexy.

Black J, Swick T, Bogan R, Lai C, Carter LP.

Sleep Med. 2016 Aug;24:57-62. doi: 10.1016/j.sleep.2016.07.010. Epub 2016 Aug 22.

7.

Accurate de novo design of hyperstable constrained peptides.

Bhardwaj G, Mulligan VK, Bahl CD, Gilmore JM, Harvey PJ, Cheneval O, Buchko GW, Pulavarti SV, Kaas Q, Eletsky A, Huang PS, Johnsen WA, Greisen PJ, Rocklin GJ, Song Y, Linsky TW, Watkins A, Rettie SA, Xu X, Carter LP, Bonneau R, Olson JM, Coutsias E, Correnti CE, Szyperski T, Craik DJ, Baker D.

Nature. 2016 Oct 20;538(7625):329-335. doi: 10.1038/nature19791. Epub 2016 Sep 14.

8.

Simulation for Milestone Assessment: Use of a Longitudinal Curriculum for Pediatric Residents.

Frey-Vogel AS, Scott-Vernaglia SE, Carter LP, Huang GC.

Simul Healthc. 2016 Aug;11(4):286-92. doi: 10.1097/SIH.0000000000000162.

PMID:
27093513
9.

Discrepancies in After-Hours Communication Attitudes between Pediatric Residents and Supervising Physicians.

Palakshappa D, Carter LP, El Saleeby CM.

J Pediatr. 2015 Dec;167(6):1429-35.e2. doi: 10.1016/j.jpeds.2015.08.052. Epub 2015 Sep 26.

PMID:
26411863
10.

A Practical Approach to the Oncology Patient With Heart Failure.

Carter LP, Clarke BA.

Can J Cardiol. 2015 Dec;31(12):1489-92. doi: 10.1016/j.cjca.2015.05.002. Epub 2015 May 8. Review.

PMID:
26321357
11.

Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential.

Reissig CJ, Harrison JA, Carter LP, Griffiths RR.

Psychopharmacology (Berl). 2015 Mar;232(5):871-83. doi: 10.1007/s00213-014-3721-0. Epub 2014 Sep 9.

12.

Patients' journeys to a narcolepsy diagnosis: a physician survey and retrospective chart review.

Carter LP, Acebo C, Kim A.

Postgrad Med. 2014 May;126(3):216-24. doi: 10.3810/pgm.2014.05.2769.

PMID:
24918805
13.

Delay discounting rates: a strong prognostic indicator of smoking relapse.

Sheffer CE, Christensen DR, Landes R, Carter LP, Jackson L, Bickel WK.

Addict Behav. 2014 Nov;39(11):1682-9. doi: 10.1016/j.addbeh.2014.04.019. Epub 2014 May 5.

14.

Cognitive effects of intramuscular ketamine and oral triazolam in healthy volunteers.

Carter LP, Kleykamp BA, Griffiths RR, Mintzer MZ.

Psychopharmacology (Berl). 2013 Mar;226(1):53-63. doi: 10.1007/s00213-012-2883-x. Epub 2012 Oct 25.

15.

Acute cognitive effects of high doses of dextromethorphan relative to triazolam in humans.

Carter LP, Reissig CJ, Johnson MW, Klinedinst MA, Griffiths RR, Mintzer MZ.

Drug Alcohol Depend. 2013 Mar 1;128(3):206-13. doi: 10.1016/j.drugalcdep.2012.08.025. Epub 2012 Sep 16.

16.

High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR.

Psychopharmacology (Berl). 2012 Sep;223(1):1-15. doi: 10.1007/s00213-012-2680-6. Epub 2012 Apr 13. Erratum in: Psychopharmacology (Berl). 2013 Aug;228(3):513.

17.

What would menthol smokers do if menthol in cigarettes were banned? Behavioral intentions and simulated demand.

O'Connor RJ, Bansal-Travers M, Carter LP, Cummings KM.

Addiction. 2012 Jul;107(7):1330-8. doi: 10.1111/j.1360-0443.2012.03822.x. Epub 2012 Apr 4.

18.

Potential impact of drug effects, availability, pharmacokinetics, and screening on estimates of drugs implicated in cases of assault.

Carter LP.

Drug Test Anal. 2011 Sep;3(9):586-93. doi: 10.1002/dta.203. Epub 2010 Dec 29. Review.

PMID:
21960542
19.

Sodium oxybate: updates and correction to previously published safety data.

Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL.

J Clin Sleep Med. 2011 Aug 15;7(4):415-6. doi: 10.5664/JCSM.1214. No abstract available.

20.

Possible role for glutamic acid decarboxylase in fibromyalgia symptoms: a conceptual model for chronic pain.

Fitzgerald CT, Carter LP.

Med Hypotheses. 2011 Sep;77(3):409-15. doi: 10.1016/j.mehy.2011.05.031.

PMID:
21684692
21.

Anticonvulsant hypersensitivity syndrome treated with intravenous immunoglobulin.

Dredge DC, Parsons EC, Carter LP, Staley KJ.

Pediatr Neurol. 2010 Jul;43(1):65-9. doi: 10.1016/j.pediatrneurol.2010.03.010.

PMID:
20682208
22.

Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion.

Wang YG, Swick TJ, Carter LP, Thorpy MJ, Benowitz NL.

J Clin Sleep Med. 2009 Aug 15;5(4):365-71. Review. Erratum in: J Clin Sleep Med. 2011 Aug 15;7(4):415-6.

23.

Abuse liability assessment of tobacco products including potential reduced exposure products.

Carter LP, Stitzer ML, Henningfield JE, O'Connor RJ, Cummings KM, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3241-62. doi: 10.1158/1055-9965.EPI-09-0948. Review.

24.

Case histories in pharmaceutical risk management.

McCormick CG, Henningfield JE, Haddox JD, Varughese S, Lindholm A, Rosen S, Wissel J, Waxman D, Carter LP, Seeger V, Johnson RE.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S42-55. doi: 10.1016/j.drugalcdep.2009.08.003. Epub 2009 Sep 19.

PMID:
19767156
25.

Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers.

Carter LP, Griffiths RR, Mintzer MZ.

Psychopharmacology (Berl). 2009 Sep;206(1):141-54. doi: 10.1007/s00213-009-1589-1. Epub 2009 Jun 20.

26.

Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse.

Carter LP, Pardi D, Gorsline J, Griffiths RR.

Drug Alcohol Depend. 2009 Sep 1;104(1-2):1-10. doi: 10.1016/j.drugalcdep.2009.04.012. Epub 2009 Jun 2. Review.

27.

Principles of laboratory assessment of drug abuse liability and implications for clinical development.

Carter LP, Griffiths RR.

Drug Alcohol Depend. 2009 Dec 1;105 Suppl 1:S14-25. doi: 10.1016/j.drugalcdep.2009.04.003. Epub 2009 May 14. Review.

28.

Eating disorder behaviors and depression: a minimal relationship beyond social comparison, self-esteem, and body dissatisfaction.

Green MA, Scott NA, Cross SE, Liao KY, Hallengren JJ, Davids CM, Carter LP, Kugler DW, Read KE, Jepson AJ.

J Clin Psychol. 2009 Sep;65(9):989-99. doi: 10.1002/jclp.20586.

PMID:
19388056
29.

Behavioral analyses of GHB: receptor mechanisms.

Carter LP, Koek W, France CP.

Pharmacol Ther. 2009 Jan;121(1):100-14. doi: 10.1016/j.pharmthera.2008.10.003. Epub 2008 Oct 29. Review.

30.

Inhibition of apoB secretion from HepG2 cells by insulin is amplified by naringenin, independent of the insulin receptor.

Allister EM, Mulvihill EE, Barrett PH, Edwards JY, Carter LP, Huff MW.

J Lipid Res. 2008 Oct;49(10):2218-29. doi: 10.1194/jlr.M800297-JLR200. Epub 2008 Jun 27.

31.

Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.

Carter LP, Griffiths RR, Suess PE, Casada JH, Wallace CL, Roache JD.

J Pharmacol Exp Ther. 2007 Aug;322(2):749-59. Epub 2007 May 14.

32.
33.

Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats.

Carter LP, Koek W, France CP.

Eur J Neurosci. 2006 Nov;24(9):2595-600.

PMID:
17100847
34.

Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.

Carter LP, Richards BD, Mintzer MZ, Griffiths RR.

Neuropsychopharmacology. 2006 Nov;31(11):2537-51. Epub 2006 Jul 26.

35.

Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348.

Carter LP, Chen W, Coop A, Koek W, France CP.

Eur J Pharmacol. 2006 May 24;538(1-3):85-93. Epub 2006 Mar 24.

PMID:
16647701
37.

Succinate semialdehyde dehydrogenase deficiency does not down-regulate gamma-hydroxybutyric acid binding sites in the mouse brain.

Mehta AK, Gould GG, Gupta M, Carter LP, Gibson KM, Ticku MK.

Mol Genet Metab. 2006 May;88(1):86-9. Epub 2006 Jan 10.

PMID:
16406647
38.

Discriminative stimulus effects of gamma-hydroxybutyrate (GHB) in rats discriminating GHB from baclofen and diazepam.

Koek W, Carter LP, Lamb RJ, Chen W, Wu H, Coop A, France CP.

J Pharmacol Exp Ther. 2005 Jul;314(1):170-9. Epub 2005 Mar 17.

39.

Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all, of the behavioral effects of GHB and GABAB receptor agonists.

Carter LP, Wu H, Chen W, Matthews MM, Mehta AK, Hernandez RJ, Thomson JA, Ticku MK, Coop A, Koek W, France CP.

J Pharmacol Exp Ther. 2005 Jun;313(3):1314-23. Epub 2005 Mar 15.

40.

Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV).

Carter LP, Chen W, Wu H, Mehta AK, Hernandez RJ, Ticku MK, Coop A, Koek W, France CP.

Drug Alcohol Depend. 2005 Apr 4;78(1):91-9.

PMID:
15769562
41.

The Discriminative stimulus effects of gamma-hydroxybutyrate and related compounds in rats discriminating baclofen or diazepam: The role of GABA(B) and GABA(A) receptors.

Carter LP, Unzeitig AW, Wu H, Chen W, Coop A, Koek W, France CP.

J Pharmacol Exp Ther. 2004 May;309(2):540-7. Epub 2004 Jan 23.

42.

Discriminative stimulus effects of gamma-hydroxybutyrate in pigeons: role of diazepam-sensitive and -insensitive GABA(A) and GABA(B) receptors.

Koek W, Flores LR, Carter LP, Lamb RJ, Chen W, Wu H, Coop A, France CP.

J Pharmacol Exp Ther. 2004 Mar;308(3):904-11. Epub 2004 Jan 12.

43.

Effects of gamma-hydroxybutyrate (GHB) on schedule-controlled responding in rats: role of GHB and GABAB receptors.

Carter LP, Wu H, Chen W, Cruz CM, Lamb RJ, Koek W, Coop A, France CP.

J Pharmacol Exp Ther. 2004 Jan;308(1):182-8. Epub 2003 Oct 20.

44.

The role of GABAB receptors in the discriminative stimulus effects of gamma-hydroxybutyrate in rats: time course and antagonism studies.

Carter LP, Flores LR, Wu H, Chen W, Unzeitig AW, Coop A, France CP.

J Pharmacol Exp Ther. 2003 May;305(2):668-74. Epub 2003 Feb 11.

45.

A tertiary alcohol analog of gamma-hydroxybutyric acid as a specific gamma-hydroxybutyric acid receptor ligand.

Wu H, Zink N, Carter LP, Mehta AK, Hernandez RJ, Ticku MK, Lamb R, France CP, Coop A.

J Pharmacol Exp Ther. 2003 May;305(2):675-9. Epub 2003 Jan 21.

46.

Pediatric eighth cranial nerve schwannoma without evidence of neurofibromatosis.

Mendel RC, Brumback RA, Leech RW, Van Campen LE, Wilson DA, Britton BH, Carter LP.

J Child Neurol. 1999 Jan;14(1):67-9.

PMID:
10025539
47.

ICP-CBF trauma bolt, laboratory evaluation.

Brennan J, Tompkins P, Stevens FA, Carter LP.

Acta Neurochir Suppl. 1998;71:40-1.

PMID:
9779138
48.
49.

Cerebral blood flow and temporal lobe epileptogenicity.

Weinand ME, Carter LP, el-Saadany WF, Sioutos PJ, Labiner DM, Oommen KJ.

J Neurosurg. 1997 Feb;86(2):226-32.

PMID:
9010424
50.

Thermal diffusion flowmetry.

Carter LP.

Neurosurg Clin N Am. 1996 Oct;7(4):749-54. Review.

PMID:
8905786

Supplemental Content

Loading ...
Support Center